Journal article icon

Journal article

Gemcitabine-induced TIMP1 attenuates therapy response and promotes tumor growth and liver metastasis in pancreatic cancer

Abstract:

Gemcitabine constitutes one of the backbones for chemotherapy treatment in pancreatic ductal adenocarcinoma (PDAC), but patients often respond poorly to this agent. Molecular markers downstream of gemcitabine treatment in pre-clinical models may provide an insight into resistance mechanisms. Using cytokine arrays, we identified potential secretory biomarkers of gemcitabine resistance (response) in the transgenic KRasG12D; Trp53R172H; Pdx-1 Cre (KPC) mouse model of PDAC. We verified the oncoge...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Accepted Manuscript

Actions


Access Document


Files:
Publisher copy:
10.1158/0008-5472.CAN-16-2833

Authors


More by this author
Department:
Oxford, MSD, Oncology
More by this author
Department:
Oxford, MSD, Oncology
More by this author
Department:
Oxford, MSD, Oncology
More by this author
Department:
Oxford, MSD, NDM, Oxford Ludwig Institute
More by this author
Department:
Oxford, MSD, Oncology
Expand authors...
More from this funder
Funding agency for:
D'Costa, Z
More from this funder
Funding agency for:
McKenna, WG
More from this funder
Grant:
C5255/A15935; A19277
Publisher:
American Association for Cancer Research Publisher's website
Journal:
Cancer Research Journal website
Volume:
77
Issue:
21
Pages:
5952-5962
Publication date:
2017-08-01
DOI:
EISSN:
1538-7445
ISSN:
0008-5472
Pubs id:
pubs:713208
URN:
uri:db76c8a0-fc70-45a7-abed-2807d2a451a7
UUID:
uuid:db76c8a0-fc70-45a7-abed-2807d2a451a7
Local pid:
pubs:713208

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP